[ Inside the business ]
NVS stock analysis
NVS · Novartis Ag
Pharmaceutical preparations.
Nothing unusual in its latest filings.
The future, in 7 questions
Needs today's sales, share count and price.
Not among the companies mentioning Radar's technologies most.
- Moves strongly with the S&P 500
From SEC filings, price and Radar. Not advice.
The record
Early signals
Quiet.
Early signals
Quiet.
What just happened
No new 8-K filings since the last report.
Signals in the filings
Early signals· full write-up
Quiet.
Early signals Quiet
What's changing in the filings before it shows up in yearly results. Signals, not predictions.
New since last report (Feb 4, 2026)
No new 8-K filings since the last periodic report.
Signals in the filings
What could go wrong
Steadier than most.
It has moved 0.5× the market. In the 2008 crisis it fell 27% while the market fell 51%.
What could go wrong
Steadier than most.
Red-flag scan, last 3 years
Past shocks replayed stock S&P 500
What could go wrong· full write-up
Steadier than most.
8 · What could go wrong
Warning signs in the filings, debt, how it reacts to the economy, and the risks it names
Red-flag scan, last 3 years
Modeled on the SEC's published Accounting Quality Model description, not SEC scores
Debt and leverage
Not available in the company's structured filings.
Macro risk 118 months to Oct 2026 Calculated
Stress test: past shocks replayed stock vs. S&P 500, month-end prices
Right now: last 3 months Reported
What if the market falls?
Historically, about -9% for this stock
Based on its 0.47× pattern. Real moves vary a lot, as the stress test shows.
What they sell
Not broken out.
The filings don't split revenue by product in structured data.
What they sell
Not broken out.
Not broken out by product in its structured filings.
What they sell· full write-up
Not broken out.
1 · What they sell
Not available: the company's filings don't break revenue down by product or segment in structured data.
Rivals it names: The race to harness AI is intensifying, as competitors seek tangible benefits, including faster trial execution, improved yield, and AI-discovered biologics in clinical development. From 10-K
Where each dollar goes
Not available.
Cost lines aren't reported in a comparable form.
Where each dollar goes
Not available.
Cost lines aren't reported in a comparable form.
Where each dollar goes· full write-up
Not available.
3 · Where each $1 goes
Not available: no revenue figure found in the company's structured SEC data.
Its market
1.5× the economy.
The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.
Its market
1.5× the economy.
Output growth a year, 2025–35, after inflation
Its market· full write-up
1.5× the economy.
2 · Where its markets head (10 years)
U.S. industry output growth after inflation, 2025–35
Projected to grow 1.5× as fast as the economy. Jobs in the industry: +0.7% a year. Gov projection
U.S. Bureau of Labor Statistics, Employment Projections 2025–35 (Table 2.11), released Aug 27, 2026
Market size and share
Your call.
There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.
Market size and share
Your call.
4 · Market size and share
Not available: no market size was found in the company's SEC filings. Companies usually give these in investor presentations, which aren't part of their official filings.
Market capture
Needs a market size (above). Nothing is assumed.
Life cycle
Not applicable.
Cash flow patterns don't describe a life cycle for banks and insurers, or the totals aren't reported.
Life cycle
Not applicable.
Life cycle stage
Not available: either the cash flow totals aren't in the company's structured filings, or it's a bank or insurer, where cash flow patterns don't describe a life cycle.
Earnings quality
Can't score.
The inputs aren't in its structured filings.
Earnings quality
Can't score.
M-score inputs aren't in its structured filings.
Earnings quality· full write-up
Can't score.
5 · Earnings quality
Are the profits backed by cash?
Not available.
Not available: the cash flow and balance sheet lines needed aren't in the company's structured filings.
Competitive advantage
Not measurable.
Returns on capital can't be computed from its filings (common for banks and insurers).
Competitive advantage
Not measurable.
Returns on capital can't be computed from its filings.
Competitive advantage· full write-up
Not measurable.
6 · Competitive advantage
Not available: operating profit and capital aren't in the company's structured filings.
Future bets
Not reported.
No research, equipment or commitment figures in its structured filings.
Future bets
Not reported.
Where the money for the years ahead goes
No figures in its structured filings.
Future bets· full write-up
Not reported.
7 · Future bets
Where is it putting money for the years ahead? Plans and commitments, not outcomes.
Not available in the company's structured filings.
All figures from Novartis Ag's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.